ArticleCureus2025
A Rare Case of Antinuclear Antibody-Negative Systemic Lupus Erythematosus Presenting With Generalized Lymphadenopathy as the Initial Manifestation.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder characterized by multisystem involvement and the presence of antinuclear antibodies (ANA). However, a subset of patients, particularly in the pediatric population, present with ANA-negative SLE, posing significant diagnostic challenges. This phenomenon is notably rare in South Asia, where ANA positivity is typically prevalent in SLE cases. The rarity of ANA-negative pediatric SLE underscores the necessity for heightened clinical vigilance and comprehensive diagnostic evaluation. We report the case of a 16-year-old South Asian female patient who presented with generalized lymphadenopathy (LAD), fever, alopecia, oral ulcers, purpuric rashes, and polyarthritis. Despite the absence of detectable ANA (tested by enzyme-linked immunosorbent assay (ELISA); immunofluorescence (IF) was not performed due to resource limitations), the patient exhibited strongly positive anti-double-stranded DNA antibody (anti-dsDNA) antibodies, fulfilling four American College of Rheumatology (ACR) classification criteria for SLE. The patient responded positively to corticosteroid and hydroxychloroquine therapy, with subsequent resolution of symptoms and stabilization of blood counts. ANA-negative pediatric SLE is an uncommon but clinically significant entity in South Asia. This case emphasizes the importance of applying comprehensive diagnostic criteria, such as the Systemic Lupus International Collaborating Clinics (SLICC) 2012, when ANA is negative. Clinicians should maintain a high index of suspicion for SLE in pediatric patients with multisystem involvement, ensuring early recognition and treatment to optimize outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.